PCI Biotech starts dosing in Phase I extension study for bile duct cancer

Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news